The pharmacokinetics of ciprofloxacin in patients with impaired renal function. 1985

J Boelaert, and Y Valcke, and M Schurgers, and R Daneels, and M Rosseneu, and M T Rosseel, and M G Bogaert

Pharmacokinetics of ciprofloxacin after single oral administration of 250 mg were studied in patients with and without renal failure. Ciprofloxacin concentrations were measured by HPLC. The elimination half-life was 8.7 +/- 0.9 h (mean +/- S.E.M.) in six renal failure patients not on haemodialysis, as compared to 4.4 +/- 0.2 h in six patients with normal renal function. The urinary recovery of unchanged ciprofloxacin was 5.3 +/- 1.7% of dose over 24 h in the renal failure patients, as compared to 37.0 +/- 3.7% in the patients with normal renal function. In haemodialysis patients, the half-life was 5.8 +/- 0.9 h on an interdialysis day, and 3.2 +/- 0.4 h during haemodialysis.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011804 Quinolines
D002939 Ciprofloxacin A broad-spectrum antimicrobial carboxyfluoroquinoline. Bay-09867,Ciprinol,Cipro,Ciprofloxacin Hydrochloride,Ciprofloxacin Hydrochloride Anhydrous,Ciprofloxacin Monohydrochloride Monohydrate,Anhydrous, Ciprofloxacin Hydrochloride,Bay 09867,Bay09867,Hydrochloride Anhydrous, Ciprofloxacin,Hydrochloride, Ciprofloxacin,Monohydrate, Ciprofloxacin Monohydrochloride,Monohydrochloride Monohydrate, Ciprofloxacin
D005260 Female Females
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

J Boelaert, and Y Valcke, and M Schurgers, and R Daneels, and M Rosseneu, and M T Rosseel, and M G Bogaert
May 1987, Antimicrobial agents and chemotherapy,
J Boelaert, and Y Valcke, and M Schurgers, and R Daneels, and M Rosseneu, and M T Rosseel, and M G Bogaert
January 1989, International journal of clinical pharmacology research,
J Boelaert, and Y Valcke, and M Schurgers, and R Daneels, and M Rosseneu, and M T Rosseel, and M G Bogaert
November 1986, The Journal of antimicrobial chemotherapy,
J Boelaert, and Y Valcke, and M Schurgers, and R Daneels, and M Rosseneu, and M T Rosseel, and M G Bogaert
April 2003, British journal of clinical pharmacology,
J Boelaert, and Y Valcke, and M Schurgers, and R Daneels, and M Rosseneu, and M T Rosseel, and M G Bogaert
September 1982, The Journal of antimicrobial chemotherapy,
J Boelaert, and Y Valcke, and M Schurgers, and R Daneels, and M Rosseneu, and M T Rosseel, and M G Bogaert
November 1976, The Journal of infectious diseases,
J Boelaert, and Y Valcke, and M Schurgers, and R Daneels, and M Rosseneu, and M T Rosseel, and M G Bogaert
January 1988, Drugs under experimental and clinical research,
J Boelaert, and Y Valcke, and M Schurgers, and R Daneels, and M Rosseneu, and M T Rosseel, and M G Bogaert
April 1993, Antimicrobial agents and chemotherapy,
J Boelaert, and Y Valcke, and M Schurgers, and R Daneels, and M Rosseneu, and M T Rosseel, and M G Bogaert
October 1986, The Japanese journal of antibiotics,
J Boelaert, and Y Valcke, and M Schurgers, and R Daneels, and M Rosseneu, and M T Rosseel, and M G Bogaert
January 1990, Drugs,
Copied contents to your clipboard!